Cheryl Cohen's recent SEC filing reveals significant stock transactions involving ImmunityBio, Inc. This activity is noteworthy as it may influence investor perceptions and the competitive landscape in the biological products industry.
On October 6, 2026, Cohen filed a Form 4 with the SEC, detailing transactions that occurred on October 2, 2026. The filing indicates that Cohen acquired 55,979 shares of ImmunityBio's common stock at a price of $2.98 per share. Additionally, she disposed of 81,056 shares at a price of $10.50 per share. Following these transactions, Cohen holds a total of 100,309 shares.
The filing also notes that the sale of shares was executed under a Rule 10b5-1 trading plan, which allows for pre-arranged stock sales to mitigate risks related to insider trading. This structured approach suggests a calculated strategy in managing her stock ownership.
Cohen's transactions could have implications for both the company and the broader industry. As a director of ImmunityBio, her actions may be scrutinized by investors and analysts, potentially affecting the company's stock performance and investor confidence.
ImmunityBio, Inc., based in San Diego, California, specializes in biological products, as indicated by its SIC classification. The company has undergone several name changes in the past, previously operating as NantKwest, Inc. and ZelleRx Corp, among others. This history reflects its evolving focus within the life sciences sector.
The filing does not specify what actions may follow these transactions, leaving investors to speculate on the potential impacts on ImmunityBio and its market position.